Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.
Maryam OroujeniJavad GarousiKen G AnderssonJohn LöfblomBogdan MitranAnna OrlovaVladimir TolmachevPublished in: Cells (2018)
2377 was efficiently (isolated yield of 73 ± 3%) and stably labeled with 68Ga. Binding of [68Ga]Ga-DFO-ZEGFR:2377 to EGFR-expressing cells in vitro was receptor-specific and proportional to the EGFR expression level. In vivo saturation experiment demonstrated EGFR-specific accumulation of [68Ga]Ga-DFO-ZEGFR:2377 in A431 xenografts. Compared to [89Zr]Zr-DFO-ZEGFR:2377, [68Ga]Ga-DFO-ZEGFR:2377 demonstrated significantly (p < 0.05) higher uptake in tumors and lower uptake in spleen and bones. This resulted in significantly higher tumor-to-organ ratios for [68Ga]Ga-DFO-ZEGFR:2377. In conclusion, [68Ga]Ga-DFO-ZEGFR:2377 is a promising probe for imaging of EGFR expression.
Keyphrases
- pet ct
- small cell lung cancer
- pet imaging
- positron emission tomography
- epidermal growth factor receptor
- tyrosine kinase
- high resolution
- stem cells
- computed tomography
- mass spectrometry
- bone marrow
- binding protein
- photodynamic therapy
- long non coding rna
- cell proliferation
- endoplasmic reticulum stress
- transcription factor
- dna binding
- fluorescence imaging